WO2010041253A1 - Compositions comprising cb receptor agonists, uses thereof and methods for their preparation - Google Patents

Compositions comprising cb receptor agonists, uses thereof and methods for their preparation Download PDF

Info

Publication number
WO2010041253A1
WO2010041253A1 PCT/IL2009/000964 IL2009000964W WO2010041253A1 WO 2010041253 A1 WO2010041253 A1 WO 2010041253A1 IL 2009000964 W IL2009000964 W IL 2009000964W WO 2010041253 A1 WO2010041253 A1 WO 2010041253A1
Authority
WO
WIPO (PCT)
Prior art keywords
branched
straight
compound
composition according
disease
Prior art date
Application number
PCT/IL2009/000964
Other languages
French (fr)
Inventor
Itai Bab
Raphael Mechoulam
Aviva Breuer
Naama Mussai
Original Assignee
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. filed Critical Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd.
Priority to EP09760006.8A priority Critical patent/EP2346804B1/en
Priority to US13/122,662 priority patent/US9428431B2/en
Publication of WO2010041253A1 publication Critical patent/WO2010041253A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/20Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01Preparation of ethers
    • C07C41/18Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/26Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/14Preparation of carboxylic acid esters from carboxylic acid halides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/28Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/29Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by introduction of oxygen-containing functional groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/28Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/293Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/36Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Definitions

  • This invention relates to compositions comprising diastereomeric CB receptor agonists, uses thereof and methods of their preparation.
  • skeletal mass is determined by continuous remodeling consisting of the concerted and balanced action of osteoclasts, the bone resorbing cells, and osteoblasts, the bone forming cells.
  • CB2 cannabinoid receptor
  • the CB2 specific agonist HU-308 (WO 2004/103410; Hanus et al, 1999), stimulates in vitro osteoblastogenesis and inhibits osteoclastogenesis.
  • HU-308 stimulates bone formation and inhibits bone resorption, thus attenuating ovariectomy (OVX)-induced bone loss (Ofek et al, 2006).
  • OVX ovariectomy
  • compound of general formula (I) may exist in any one of the stereisomeric forms, indicated in Table 1 below.
  • Table 1 CIP configuration of diastereomers of compounds of general formula (I)
  • compound of general formula (I 1 ) may exist in any one of the stereoisomeric forms, indicated in Table 2 below.
  • Table 2 CIP configuration of diastereomers of compounds of general formula (I 1 )
  • positions 4 and 6 are both located at the - A - bridgeheads of the bicyclic ring system, their stereochemistry is interconnected and diastereomers (IR, 3R, AR, 6S), (IS, 3R, AR, 6S), (IR, 3S, AR, 6S), (IS, 35, AR, 6S), (IR, 3R, AS, 6R), (IS, 3R, AS, 6R), (IR, 3S, AS, 6R) and (IS, 3S, AS, 6R) (corresponding to stereoisomers 9, 10, 11, 12, 13, 14, 15, 16 in Table 2 above) do not exist under typical processing and thermal conditions.
  • the present invention provides a composition comprising the (3R, AR, 6R)- diastereomer of a compound of general formula (II):
  • composition having diastereomeric ratio of between about 50%: 50% to about 100%:0%; wherein is a single or double bond;
  • R 2 is a Ci-C 5 straight or branched alkylene
  • R 4 , and R 5 are independently selected from the group consisting of H, OH, straight or branched Ci-C 5 alkyl, straight or branched Ci-Csalkoxy, straight or branched Ci-C 5 amine;
  • R 6 and R 7 are each independently selected from H, and -OR 8 wherein R 8 is a straight or branched Ci-C 5 alkyl, provided that at least one Of R 6 and R 7 is different than H (i.e. provided that at least one OfR 6 and R 7 is -OR 8 ); and
  • R 9 is independently selected from an optionally substituted straight or branched C 6 -C] 2 alkyl, an optionally substituted straight or branched C 5 -C 9 alkoxy, an optionally substituted straight or branched C 1 -C 7 ether.
  • the invention provides a composition comprising the (3R, AR, 6i?)-diastereomer of a compound of general formula (II), said composition having diatereomeric excess of between about 0% to about 100%;wherein is a single or double bond;
  • R 2 is a Ci-C 5 straight or branched alkylene;
  • R 3 is selected from the group consisting of H, straight or branched C 1 -C 5 alkyl, straight or branched C 1 -C 5 acyl, straight or branched C 1 -C 5 amide;
  • R 4 , and R 5 are independently selected from the group consisting of H, OH, straight or branched Cj-C 5 alkyl, straight or branched Cj-C 5 alkoxy, straight or branched C 1 -Cs amine;
  • R 6 and R 7 are each independently
  • R 1 is -R 2 OR 3
  • H i.e. leading to a substitution with an aldehyde group
  • straight or branched Cj-C 5 alkyl i.e. leading to a substitution with a
  • a compound of formula (II) is: wherein R 1 , R 6 , R 7 , and R 9 are have the same meaning as defined hereinabove.
  • Ri, R 6 , R 7 , and R 9 are have the same meaning as defined hereinabove.
  • diastereomeric ratio as used herein is meant to encompass the ratio of the percentage of one diastereoisomer in a mixture to that of another diastereoisomer of a compound of formula (I).
  • said diastereomeric ratio indicates the percentage ratio between (3R, AR, 6 ⁇ )-diastereomer of a compound of general formula (I) (compound of formula (III)), and each of (3S, AR, 6R)- or (3R, 45, 65)-diastereomers, all of which (together or individually) may be present in said composition of the invention.
  • composition of the invention has a diastereomeric ratio of 50%:50%, it should be understood that the ratio between the (3R, AR, 6/?)-diastereomer of a compound of general formula (I) (compound of formula (III)) and any one of the diastereomers (35, AR, 6R)- or (3R, AS, 6S)- diastereomer, present in said composition is about 1 :1.
  • a composition of the invention has a diastereomeric ratio of about 100%:0%, it should be understood that the composition comprises essentially only the (3i?, AR, 6i?)-diastereomer of a compound of general formula (I), (compound of formula (III)).
  • composition of the present invention may comprise any mixture of (3R, AR, 6i?)-diastereomer of a compound of general formula (I) (compound of formula (III)) with one or more of its diastereomers ((35,4i?,6i?)- or (3R,AS,6S)- diastereomers), such as for example a composition having a diatereomeric ratio of 50%:50%, 70%:30%, 80%:20%, 90%: 10%, 95%:5%, 97%:3%, 99%: 1% or 100%:0%.
  • said diastereomeric ratio is at least 97%:3%.
  • said diastereomeric ratio indicates the percentage ratio between (Ii?, 3R, AR, 6R)- diastereomer of a compound of general formula (I 1 ) (compound of formula (IV))and each of (IS, 3R, AR, 6R)-, ( ⁇ R, 35, AS, 65) , ( ⁇ R, 35, AR, 6R)-, (15, 35, AR, 6R)-, ( ⁇ R, 3R, AS, 6S)- or (15, 3R, AS, 65)-diastereomers, all of which (together or individually) may be present in said composition of the invention.
  • composition of the invention has a diastereomeric ratio of 50%:50%, it should be understood that the ratio between the (Ii?, 3i?, 4i?, 6i?)-diastereomer of a compound of general formula (I 1 ) (compound of formula (IV)) and any one of the diastereomers (15, 3R, AR, 6R)-, (Ii?, 35, 45, 65) , (Ii?, 35, 4i?, 6R)-, (15, 35, AR, 6R)-, (Ii?, 3i?, 45, 65)- or (15, 3i?, 45, 65)-diastereomer, present in said composition is about 1:1.
  • composition of the invention has a diastereomeric ratio of about 100%:0%, it should be understood that the composition comprises essentially only the (Ii?, 3i?, 4i?, 6i?)-diastereomer of a compound of general formula (I 1 ) (compound of formula (IV)).
  • composition of the present invention may comprise any mixture of (Ii?, 3i?, 4i?, 6i?)-diastereomer of a compound of general formula (T) (compound of formula (IV)) with one or more of its diastereomers ((15, 3i?, 4i?, 6i?)-, (Ii?, 35, 45, 65) , (Ii?, 35, 4i?, 6i?)-, (15, 35, 4i?, 6i?)-, (Ii?, 3i?, 45, 65)- or (15, 3i?, 45, 65)- diastereomers), such as for example a composition having a diatereomeric ratio of 50%:50%, 70%:30%, 80%:20%, 90%: 10%, 95%:5%, 97%:3%, 99%: 1% or 100%:0%. In some embodiments of the invention, said diastereomeric ratio is at least 97%:3%.
  • said diastereomeric ratio indicates the percentage ratio between (15, 3i?, 4i?, 6i?)- diastereomer of a compound of general formula (I 1 ) (compound of formula (IV)) and each of (li?, 3R, AR, 6R)-, (15, 35, 45, 65), (Ii?, 35, AR, 6R)-, (15, 35, AR, 6R)-, (Ii?, 3i?, 45, 65)- or (15, 3i?, 45, 65)-diastereomers, all of which (together or individually) may be present in said composition of the invention.
  • composition of the invention has a diastereomeric ratio of 50%:50%
  • composition of the invention has a diastereomeric ratio of about 100%:0%, it should be understood that the composition comprises essentially only the (15, 3i?, 4i?, 6i?)-diastereomer of a compound of general formula (I 1 ) (compound of formula (IV)).
  • the composition of the present invention may comprise any mixture of (15, 3i?, 4i?, 6i?)-diastereomer of a compound of general formula (I 1 ) with one or more of its diastereomers ((15, 3i?, 4i?, 6i?)-, (Ii?, 35, 45, 65) , (Ii?, 35, 4i?, 6i?)-, (15, 35, 4i?, 6i?)-, (Ii?, 3i?, 45, 65)- or (15, 3i?, 45, 65)-diastereomers), such as for example a composition having a diatereomeric ratio of 50%:50%, 70%:30%, 80%:20%, 90%:10%, 95%:5%, 97%:3%, 99%: 1% or 100%:0%. In some embodiments of the invention, said diastereomeric ratio is at least 97%:3%.
  • diatereomeric excess as used herein is meant to encompass the subtraction of the mole fraction of one diastereoisomer (D 1 ) from the mole fraction of another diastereoisomer (D 2 ) in a composition, i.e. D 1 - D 2 .
  • This term may alternatively relate to the percent diastereoisomer excess as 100%*(A-A>)-
  • said diastereomeric excess indicates the excess in a composition of the invention of (3i?, 4i?, 6i?)-diastereomer of a compound of general formula (I) with respect to each of (35,4i?,6i?)-,or (3i?,45,65)-, diastereomer of compound of general formula (I), all of which (together or individually) may be present in said composition of the invention.
  • the diastereomeric excess of a composition of the invention is 0% the mole fraction of (3i?, 4i?, 6i?)-diastereomer of a compound of general formula (I), is essentially equal to the mole fraction of any one of of (35, 4i?, 6R)-, or (3i?, 45, 65)- diastereomer of compound of general formula (I).
  • the diastereomeric excess of a composition of the invention is 100% the composition comprises substantially only the (3i?, 4i?, 6i?)-diastereomer of a compound of general formula (I).
  • composition of the present invention may comprise any mixture of (3i?, 4i?, 6i?)-diastereomer of a compound of general formula (I) with one or more of its diastereomers ((35,4i?,6i?)-, or (3i?,45,65)- diastereomers), such as for example a composition having a diastereomeric excess of 0%, 5%, 10%, 20%, 30%, 50%, 80%, 90%, 95%, 97%, 98%, 99%, or 100%. In some embodiments of the invention, said diastereomeric excess is at least 97%.
  • said diastereomeric excess indicates the excess in a composition of the invention of (Ii?, 3i?, AR, 6R)- diastereomer of a compound of general formula (I 1 ) (compound of formula (IV)) with respect to each of (15, 3R, AR, 6R)-, (Ii?, 35, 45, 65), ( ⁇ R, 35, AR, 6R)-, (15, 35, AR, 6R)-, ( ⁇ R, 3R, 45, 65)- or (15, 3R, 45, 65)-diastereomers, all of which (together or individually) may be present in said composition of the invention.
  • the mole fraction of (IR, 3R, AR, 6i?)-diastereomer of a compound of general formula (I 1 ) is essentially equal to the mole fraction of any one of (15, 3R, AR, 6R)-, ( ⁇ R, 35, 45, 65) , (Ii?, 35, AR, 6R)-, (15, 35, 4i?, 6i?)-, (Ii?, 3i?, 45, 65)- or (15, 3i?, 45, 65)-diastereomers.
  • composition of the invention comprises substantially only the (Ii?, 3i?, 4i?, 6i?)- diastereomer of a compound of general formula (I 1 ) (compound of formula (IV)).
  • composition of the present invention may comprise any mixture of (Ii?, 3i?, 4i?, 6i?)- diastereomer of a compound of general formula (I 1 ) (compound of formula (IV)) with one or more of its diastereomers ((15, 3i?, 4i?, 6i?)-, (Ii?, 35, 45, 65) , (Ii?, 35, 4i?, 6i?)-, (15, 35, 4i?, 6i?)-, (Ii?, 3i?, 45, 65)- or (15, 3i?, 45, 65)-diastereomers), such as for example a composition having a diastereomeric excess of 0%, 5%, 10%, 20%, 30%, 50%, 80%, 90%, 95%, 97%, 98%, 99%, or 100%. In some embodiments of the invention, said diastereomeric excess is at least 97%.
  • said diastereomeric excess indicates the excess in a composition of the invention of (15, 3i?, 4i?, 6i?)-diastereomer of a compound of general formula (I 1 ) (compound of formula (IV)) with respect to each of (Ii?, 3i?, 4i?, 6i?)-, (15, 35, 45, 65), (Ii?, 35, 4i?, 6i?)-, (15, 35, 4i?, 6i?)-, (Ii?, 3i?, 45, 65)- or (15, 3i?, 45, 65)-diastereomers, all of which (together or individually) may be present in said composition of the invention.
  • the mole fraction of (15, 3i?, 4i?, 6i?)-diastereomer of a compound of general formula (I 1 ) is essentially equal to the mole fraction of any one of (Ii?, 3i?, 4i?, 6i?)-, (15, 35, 45, 65), (Ii?, 35, 4i?, 6i?)-, (15, 35, 4i?, 6i?)-, (Ii?, 3i?, 45, 65)- or (IiS, 3R, AS, 6S)-diastereomers.
  • the composition of the present invention may comprise any mixture of (IS, 3R, AR, 6R)- diastereomer of a compound of general formula (I 1 ) (compound of formula (IV)) with one or more of its diastereomers ((IR, 3R, AR, 6R)-, (IS, 3S, AS, 6S), (IR, 3S, AR, 6R)-, (IS, 3S, AR, 6R)-, ( ⁇ R, 3 R, AS, 6S)- or (IS, 3 R, AS, 6S)-diastereomers), such as for example a composition having a diastereomeric excess of 0%, 5%, 10%, 20%, 30%, 50%, 80%, 90%, 95%, 97%, 98%, 99%,
  • composition of the invention has an enantiomeric excess of between about 100% to more than about 0%.
  • enantiomeric excess (also denoted “ee") is meant to encompass a percent excess of an enantiomer (Ei or E 2 ) over the racemic mixture (1 :1 mixture of Ei and E 2 ), in accordance with eq.1 below:
  • enantiomer Ei it should be understood to encompass substantially only one enantiomer (Ei).
  • ee value of more than about 0% of, for example, enantiomer Ei it should be understood to encompass non racemic mixtures of Ei and E 2 .
  • said ee when indicates a double bond, indicates the percentage excess between the (3R, AR, 6R) stereoisomer of a compound of general formula (I) or (HI), and its enantiomer (3S, AS, 6S).
  • said ee when indicates a single bond, indicates the percentage excess between the (Ii?, 3R, AR, 6R) stereoisomer of a compound of general formula (I 1 ) or (IV), and its enantiomer (15, 3S, AS, 6S).
  • said ee when indicates a single bond, indicates the percentage excess between the (IS, 3R, AR, 6R) stereoisomer of a compound of general formula (I 1 ) or (IV), and its enantiomer (Ii?, 35", AS, 6S).
  • Ri is -R 2 OR 3 , wherein R 2 and R 3 are as defined hereinabove.
  • R 2 is -CH 2 -.
  • R 6 is H and R 7 is -OR 8 , wherein R 8 is a straight or branched C1-C 5 alkyl.
  • R 7 is H and R 6 is -OR 8 , wherein R 8 is a straight or branched C 1 -C 5 alkyl.
  • R 6 and R 7 are each independently -OR 8 , wherein R 8 is a straight or branched C 1 -C 5 alkyl.
  • R 9 is an optionally substituted branched C 6 -Ci 2 alkyl.
  • alkyl refers to a straight or branched chain hydrocarbon having from one to five carbon atoms, or from one to seven carbon atoms, or from five to nine carbon atoms, or from six to twelve carbon atoms.
  • alkyl as used herein include, but are not limited to, methyl, ethyl, propyl, n-butyl, n- pentyl, isobutyl, and isopropyl, tert-butyl, and the like.
  • alkylene refers to a saturated, divalent, branched or straight hydrocarbon group having from one to five carbon atoms.
  • Non-limiting examples of Ci -5 -alkylene groups include, methylene, ethylene, 1 ,2-propylene, 1,3- propylene, butylene, isobutylidene, pentylene, hexylene and the like.
  • esters is meant to encompass an -COOR group wherein R is an alkyl as defined herein above.
  • ether refers to an -R'OR group, wherein R' is a Ci-C 7 straight or branched alkylene group and R is a C 1 -C 7 straight or branched alkyl group.
  • alkoxy refers to an RO- group, where R is alkyl as defined above.
  • Cj-C ⁇ amide refers to a monoalkyl amide (-C0NHR) or dialkyl amide (-CONRR'), wherein R and R' are independently a Ci -C 7 straight or branched alkyl.
  • C 1 -C 5 amine refers to an -NHR or -NRR' group wherein R and R' are independently a Ci-C 5 straight or branched alkyl.
  • Cj-Cs alkoxy refers to a -OR group wherein R is a Q- C 5 alkyl.
  • substituents such as for example those specified above, phenyl, substituted phenyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen (-F, -Cl, -Br, -I).
  • substituents may be the same or different and said substitution may occur at any position on the substituted group (i.e. at a terminal or any mid-chain position or both).
  • said compound of formula (II) is the following compound (HU-433):
  • composition is a pharmaceutical composition.
  • pharmaceutical compositions comprising a compound of the subject invention it should be understood to encompass admixtures of compounds of the invention, with pharmaceutically acceptable auxiliaries, and optionally other therapeutic agents.
  • the auxiliaries must be "acceptable” in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.
  • compositions include those suitable for oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration or administration via an implant.
  • the compositions may be prepared by any method well known in the art of pharmacy. Such methods include the step of bringing in association compounds used in the invention or combinations thereof with any auxiliary agent.
  • Auxiliary agent(s), also named accessory ingredient(s), include those conventional in the art, such as carriers, fillers, binders, diluents, disintegrants, lubricants, colorants, flavouring agents, anti-oxidants, and wetting agents.
  • compositions suitable for oral administration may be presented as discrete dosage units such as pills, tablets, dragees or capsules, or as a powder or granules, or as a solution or suspension.
  • the active ingredient may also be presented as a bolus or paste.
  • the compositions can further be processed into a suppository or enema for rectal administration.
  • the invention further includes a pharmaceutical composition, as hereinbefore described, in combination with packaging material, including instructions for the use of the composition for a use as hereinbefore described.
  • compositions include aqueous and nonaqueous sterile injection.
  • the compositions may be presented in unit-dose or multi-dose containers, for example sealed vials and ampoules, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of sterile liquid carrier, for example water, prior to use.
  • compositions or formulations suitable for pulmonary administration e.g. by nasal inhalation include fine dusts or mists which may be generated by means of metered dose pressurized aerosols, nebulisers or insufflators.
  • the exact dose and regimen of administration of the composition will necessarily be dependent upon the therapeutic or nutritional effect to be achieved and may vary with the particular formula, the route of administration, and the age and condition of the individual subject to whom the composition is to be administered.
  • compositions comprising substantially HU-433, retained the CB2 specificity, with nearly 2-fold higher binding potency, and respective 1000- and 100-fold higher in vitro and in vivo skeletal activities, compared to HU-308.
  • a composition capable of binding to a CB receptor.
  • CB receptor is meant to encompass a cannabinoid G-protein coupled receptor, defined by their capability to bind to cannabinoids and/or endocannabinoids.
  • said receptor is a CBl (cannabinoid receptor Type 1) and/or CB2 receptor (cannabinoid receptor Type 2).
  • said receptor is a CB2 receptor (cannabinoid receptor Type 2).
  • CBl subtype receptor is mainly expressed in the brain, lungs, liver and kidneys.
  • CB2 subtype receptor is mainly expressed in the immune system and in hematopoietic cells.
  • binding of a composition of the invention to a CB receptor it is meant to include any type of association between a composition of the invention and a CB receptor, which may activate said bound receptor.
  • said composition is capable of being bound to CBl and CB2 receptors.
  • the extent of binding may be identical or different.
  • a composition of the invention binds to CB2 receptor to a greater extent as compared with the binding to CBl receptor.
  • activation of the CB2 receptor by a composition of the invention is at least 10 times higher than the activation of the CBl receptor.
  • composition of the invention is capable of binding to CB2 receptor.
  • said binding of a CB receptor by a composition of the invention is associated with a beneficial therapeutic effect, such as the treatment of a disease or disorder.
  • a beneficial therapeutic effect is evident by activation of CB receptor (in some embodiments, with low or no activation of CBl receptor) are: inflammation (Benito et al., Brit. J. Pharmacol. 153, 277-285, 2008), pain, allergies, neurological diseases - multiple sclerosis (Docagne et al., Expert Opin.
  • Alzheimer's (Benito et al., ibid), amyotropic lateral sclerosis (Kim et al., Eur J Pharmacol, 542, 100-105, 2006), HIV- induced encephalitis (Benoto et al., J. Neurosci. 25, 2530-2536, 2005), neuropathic pain (Zhang et al., Eur, J,. Neurosci, 17, 2750-2754, 2003); Huntington disease (Sagredo et al.. GUa, 57, 1154-1167 2009) ; Parkinson (Papa, SM. Exp. Neurol.
  • said disease or disorder is selected from inflammation, pain, allergies, neurological and neurodegenerative diseases, liver diseases, cerebral ischemic-reperfusion injury, cancer, retinal vascularization, endometritis, appetite related disorders, metabolic syndrome, diabetes, atherosclerosis and disorders related to anti-fibrinogenic effects and emesis or any combinations thereof.
  • composition of the invention is for use in the stimulation of bone growth, bone mass, bone repair or prevention of bone loss.
  • a composition of the invention is for the treatment of a disease or a disorder selected from osteopenia, osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, osteoarthritis, periodontal disease or defect, an osteolytic bone loss disease, post-plastic surgery, post-orthopedic surgery, post oral surgery, post-orthopedic implantation, and post-dental implantation, primary and metastatic bone cancer and osteomyelitis, or any combinations thereof.
  • said disease or disorder is selected from osteopenia and osteoporosis.
  • the present invention provides a use of a composition of the invention, for the manufacture of a medicament for activating a CB receptor.
  • the invention provides a use a composition of the invention, for the manufacture of a medicament for stimulation of bone growth, bone mass, bone repair or prevention of bone loss.
  • the invention provides a use a composition of the invention, for the manufacture of a medicament for the treatment of a disease or a disorder selected from osteopenia, osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, osteoarthritis, periodontal disease or defect, an osteolytic bone loss disease, post-plastic surgery, post-orthopedic surgery, post oral surgery, post- orthopedic implantation, and post-dental implantation, primary and metastatic bone cancer, osteomyelitis, or any combinations thereof.
  • a disease or a disorder selected from osteopenia, osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, osteoarthritis, periodontal disease or defect, an osteolytic bone loss disease, post-plastic surgery, post-orthopedic surgery, post oral surgery, post- orthopedic implantation, and post-dental implantation, primary and metastatic bone cancer, osteomyelitis, or any combinations thereof.
  • the invention provides a method for activating a CB receptor in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a composition of the invention.
  • the invention provides a method of stimulation of bone growth, bone mass, bone repair or prevention of bone loss, said method comprising administering to a subject in need thereof a therapeutically effective amount of a composition of the invention.
  • treatment refers to the administering of a therapeutic amount of the composition of the present invention which is effective to ameliorate undesired symptoms associated with a disease, to prevent the manifestation of such symptoms before they occur, to slow down the progression of the disease, slow down the deterioration of symptoms, to enhance the onset of remission period, slow down the irreversible damage caused in the progressive chronic stage of the disease, to delay the onset of said progressive stage, to lessen the severity or cure the disease, to improve survival rate or more rapid recovery, or to prevent the disease form occurring or a combination of two or more of the above.
  • the term "effective amount" means that amount of a composition of the invention that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician.
  • the effective amount for purposes disclosed herein is determined by such considerations as may be known in the art.
  • the amount must be effective to achieve the desired therapeutic effect as described above, depending, inter alia, on the type and severity of the disease to be treated and the treatment regime.
  • the effective amount is typically determined in appropriately designed clinical trials (dose range studies) and the person versed in the art will know how to properly conduct such trials in order to determine the effective amount.
  • an effective amount depends on a variety of factors including the affinity of the ligand to the receptor, its distribution profile within the body, a variety of pharmacological parameters such as half life in the body, on undesired side effects, if any, on factors such as age and gender, etc.
  • therapeutically effective amount means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder.
  • the term also includes within its scope amounts effective to enhance normal physiological function.
  • acyl chloride may be any akyl chloride for example pivaloyl chloride; oxidation of compound (VI) to obtain 4-oxo-substituted compound (VII):
  • the present invention further concerns compounds obtainable by the above method.
  • Figs. 1A-1B shows column diagram describing the stimulation of MC3T3 El osteoblastic cell number by a compound of the present invention (i.e. HU-433) (Fig. IA) and HU-308 (Fig. IB) (shown as [cell per WeIl]XlO "4 as a function of compound concentration (M). Data is mean ⁇ S.E. obtained in 3 culture wells per condition). ND, not done.
  • Figs. 2A-2B shows column diagram describing the rescue of ovariectomy (OVX)-induced loss of trabecular bone volume density (BV/TV) by a compound of the present invention (i.e. HU-433) and HU-308.
  • OVX ovariectomy
  • BV/TV trabecular bone volume density
  • Treatment commenced 6 weeks after OVX, to allow initial bone loss, and consisted of 6-week intraperitoneal administration of: 0.2 mg/Kg/day HU-433 (Fig. 2A); 20 mg/Kg/day HU-308 (Fig. 2B).
  • ⁇ CT analysis Data are mean ⁇ S.E. obtained in 6 mice per condition. (*) p ⁇ 0.05.
  • Methyl iodide (0.75ml, 12mmol) was added to a solution of 2-(3-myrtenyl pivalate)-5-dimethylheptyl resorcinol (0.7 Ig, 1.51mmol) and K 2 CO 3 (1.6g, 12mmol) in dry DMF (5 ml). After stirring at room temperature for 24h, the mixture was diluted with water (40ml) and extracted with ether. The organic layer was washed with water, dried and evaporated.
  • HU-433 pivalate (0.35g, 0.7mmol) in dry ether (20ml) was added slowly, under argon to a suspension of LiAlH4 (64 mg, 1.68mmol) an dry ether (5ml). The mixture was refluxed for 2h. The excess LiAlH 4 was destroyed with ethyl acetate followed by a saturated solution of MgSO 4 until a clear ether solution was obtained. The ether layer was decanted, dried and evaporated. The product precipitated out from pentane to give HU-433, m.p.
  • Binding of HU-308 to the CBl and CB2 cannabinoid receptors was assayed (see Hanus et al, 1999), showing Kj value of 22.7 nM. Binding of HU-433 was found to be significantly more potent, having K, value of 12.2 nM.
  • CBl receptor binding synaptosomal membranes were prepared from the brains of Sabra rats by homogenization and gradient centrifugation (Devane et al, 1992).
  • CB2 receptor binding assay COS- 7 cells were transfected with plasmids containing CB2 cDNA, and crude membranes were prepared (Munro et al, 1993).
  • the high affinity receptor probe [ 3 H]HU-243 (Tocris Cookson Ltd., United Kingdom), with a dissociation constant of 45 ⁇ 7 pM for the CBl receptor, was incubated with synaptosomal membranes (3—4 ⁇ g) for CBl assay or transfected cells for the CB2 assay, for 90 min at 30 0 C with different concentrations of the assayed ligands or with the vehicle alone (fatty acid-free bovine serum albumin at a final concentration of 0.5 mg/ml).
  • Bound and free radioligands were separated by centrifugation. The data were normalized to 100% of specific binding, which was determined with 50 nM unlabeled HU-243.
  • HU-433 >20 ⁇ M 12.2 nM HU-308 >10 ⁇ M 22.7 nM
  • Example 3 Comparative skeletal activity of HU-433 and HU-308 Osteoblastic MC3T3 El cells were cultured as reported in Miguel et al, 2005. For the last 46 hours in culture the cell were incubated with HU-433 or HU-308 added as a DMSO solution. Control cultures were treated only with the DMSO solvent (Ofek et al, 2006). In these cells, HU-433 and HU-308 doubled cell number at respective ligand concentrations of 10 "11 M and 10 "8 M, indicating that in the assay of HU-433 was a 1000-fold more active compared to HU-308 (Figs. IA and IB). Typical of this assay system, the dose-response curves are bell shaped (Miguel et al, 2005), with the peak stimulation of cell number followed by reversal of the effect to baseline levels.
  • HU-433 is at least 100-fold more active than HU-308 (at a 100 fold increase it only caused 50% of the HU-433 effect).
  • the effect of HU-433 in above in vivo test system is substantially greater than the reversal of bone volumetric density by parathyroid hormone (1-34), the only clinically approved bone anabolic agent (Alexander et al, 2001).

Abstract

The present invention relates compositions comprising (3R, 4R, 6R)-stereoisomers of phenyl substituted pinenes having CB receptor agonists properties, uses thereof for the manufacture of pharmaceutical compositions and processes for their preparations.

Description

COMPOSITIONS COMPRISING CB RECEPTOR AGONISTS, USES THEREOF AND METHODS FOR THEIR PREPARATION
FIELD OF THE INVENTION
This invention relates to compositions comprising diastereomeric CB receptor agonists, uses thereof and methods of their preparation.
BACKGROUND OF THE INVENTION
The following publications are relevant for describing the state of the art in the field of the invention:
1. L. Hanus, et al. Proc. Natl. Acad. Sci, U.S.A. 96:14228-14233, 1999.
2. O. Ofek, et al. Proc. Natl. Acad Sci. U. S A. 103:696-701, 2006.
3. I. Bab, et al. J. Neuroendocrinal. 20 Suppl 1 :69-74, 2008.
4. L. Hanus, et al. Org. Biomol. Chem. 3:1116-1123, 2005.
5. W.A. Devane, et al. Science. 258:1946-1949, 1992.
6. S. Munro, et al. Nature. 365:61-65, 1993.
7. S.M. Miguel, et al. J. Biol. Chem. 280:37495-37502, 2005.
8. J.M. Alexander, et al J. Bone Min. Res. 16:1665-1673, 2001.
9. I. Bab, et al. WO 2004/103,410
10. E. Fride et al. US 6,864,291
11. R. Mechoulam et al. US 5,434,295
In vertebrates, skeletal mass is determined by continuous remodeling consisting of the concerted and balanced action of osteoclasts, the bone resorbing cells, and osteoblasts, the bone forming cells.
Osteoporosis, the most prevalent degenerative disease in developed countries, results from the impairment of this balance, leading to bone loss and increased fracture risk. We have recently reported the expression of functional type 2 cannabinoid receptor (CB2) in bone cells.
The CB2 specific agonist HU-308 (WO 2004/103410; Hanus et al, 1999), stimulates in vitro osteoblastogenesis and inhibits osteoclastogenesis. In mice, HU-308 stimulates bone formation and inhibits bone resorption, thus attenuating ovariectomy (OVX)-induced bone loss (Ofek et al, 2006). In another mouse model it rescues OVX- induced bone loss (Bab et al, 2008).
SUMMARY OF THE INVENTION
The compound of general formula (I):
Figure imgf000003_0001
comprises three stereogenic centers, namely: carbon atom in position 3, carbon atom in position 4 and carbon atom in position 6 (substituents R1, R6, R7 and R9 are defined herein below). Thus, compound of general formula (I) may exist in any one of the stereisomeric forms, indicated in Table 1 below. Table 1: CIP configuration of diastereomers of compounds of general formula (I)
Stereoisomer CIP configuration of CIP configuration of CIP configuration of
No. position 3 position 4 position 6
1 (HU-433) R R R
2 S R R
3 R S S
4 (HU-308) S S S
5 R R S
6 S R S
7 R S R
8 S S R
However, it is noted that since positions 4 and 6 are both located at the bridgeheads of the bicyclic ring system, their stereochemistry is interconnected and diastereomers (3R, 4R, 6S), (35, 47?, 65), QR, 4S, 6R) and (35, 45, 6R) (corresponding to diastereomers 5, 6, 7 and 8 in above table) do not exist under typical processing and thermal conditions. US patent 6,864,291 disclosed a compound of general formula (I) having a configuration of (3S, 4S) (HU-308) being essentially free from its only enantiomer (having (3R, 4R) configuration), compositions and uses thereof.
The compound of general formula (I1):
Figure imgf000004_0001
comprises four stereogenic centers, namely: carbon atom in position 1, carbon atom in position 3, carbon atom in position 4 and carbon atom in position 6 (substituents Ri, R6, R7 and R9 are defined herein below). Thus, compound of general formula (I1) may exist in any one of the stereoisomeric forms, indicated in Table 2 below. Table 2: CIP configuration of diastereomers of compounds of general formula (I1)
Stereoisomer CIP configuration of CIP configuration CIP configuration CIP configuration
No. position 1 of position 3 of position 4 of position 6
1 R R R R
2 S R R R
3 R S R R
4 S S R R
5 R R S S
6 S R S S
7 R S S S
8 S S S S
9 R R R S
10 S R R S
1 1 R S R S
12 S S R S
13 R R S R
14 S R S R
15 R S S R
16 S S S R
However, it is noted that since positions 4 and 6 are both located at the - A - bridgeheads of the bicyclic ring system, their stereochemistry is interconnected and diastereomers (IR, 3R, AR, 6S), (IS, 3R, AR, 6S), (IR, 3S, AR, 6S), (IS, 35, AR, 6S), (IR, 3R, AS, 6R), (IS, 3R, AS, 6R), (IR, 3S, AS, 6R) and (IS, 3S, AS, 6R) (corresponding to stereoisomers 9, 10, 11, 12, 13, 14, 15, 16 in Table 2 above) do not exist under typical processing and thermal conditions.
The present invention provides a composition comprising the (3R, AR, 6R)- diastereomer of a compound of general formula (II):
Figure imgf000005_0001
said composition having diastereomeric ratio of between about 50%: 50% to about 100%:0%; wherein is a single or double bond;
R, is independently selected from -R2OR3, -Q=O)R4, -OC(=O)R5;
R2 is a Ci-C5 straight or branched alkylene;
R3 is selected from the group consisting of H, -C(=O)OH, straight or branched Ci-C5 alkyl, straight or branched Ci-C5 acyl, straight or branched Ci-C5 amide;
R4, and R5 are independently selected from the group consisting of H, OH, straight or branched Ci-C5 alkyl, straight or branched Ci-Csalkoxy, straight or branched Ci-C5 amine;
R6 and R7 are each independently selected from H, and -OR8 wherein R8 is a straight or branched Ci-C5 alkyl, provided that at least one Of R6 and R7 is different than H (i.e. provided that at least one OfR6 and R7 is -OR8); and
R9 is independently selected from an optionally substituted straight or branched C6-C]2 alkyl, an optionally substituted straight or branched C5-C9 alkoxy, an optionally substituted straight or branched C1-C7 ether.
In a further aspect, the invention provides a composition comprising the (3R, AR, 6i?)-diastereomer of a compound of general formula (II), said composition having diatereomeric excess of between about 0% to about 100%;wherein is a single or double bond; R1 is independently selected from -R2OR3, -Ct=O)R4, -OC(=O)R5; R2 is a Ci-C5 straight or branched alkylene; R3 is selected from the group consisting of H, straight or branched C1-C5 alkyl, straight or branched C1-C5 acyl, straight or branched C1-C5 amide; R4, and R5 are independently selected from the group consisting of H, OH, straight or branched Cj-C5 alkyl, straight or branched Cj-C5alkoxy, straight or branched C1-Cs amine; R6 and R7 are each independently selected from H, and -OR8 wherein R8 is a straight or branched C1-Cs alkyl, provided that at least one Of R6 and R7 is different than H; and R9 is independently selected from an optionally substituted straight or branched C6-C12 alkyl, an optionally substituted straight or branched C5-C9 alkoxy, an optionally substituted straight or branched C1-C7 ether.
It is noted that in an embodiment where R1 is -R2OR3, R2 is a C1-Cs straight or branched alkylene and R3 is selected from the group consisting of H (i.e. leading to a substitution with an alcohol group), straight or branched C1-C5 alkyl (i.e. leading to a substitution with an ether group), straight or branched C1-Cs acyl (i.e. leading to a substitution with an ester group), -C(=0)0H (i.e. leading to a substitution with a -C1- C5alkyl-OC(=O)OH group) and a straight or branched C1-C5 amide (i.e. leading to a substitution with an amide ester group).
In another embodiment where R1 is -Q=O)R4, R4 is selected from a group consisting of H (i.e. leading to a substitution with an aldehyde group); OH, (i.e. leading to a substitution with an acetic acid group), straight or branched C1-C5 alkyl (i.e. leading to a substitution with a ketone group), straight or branched Ci-C5 alkoxy (i.e. leading to a substitution by a -C(=0)0R group) and a straight or branched Cj-C5 amine (i.e. leading to a substitution by a -C(=0)NHR or -C(=0)NR'R group).
In a further embodiment where Rj is -0C(=0)R5, R5 is selected from a group consisting of H (i.e. leading to a substitution with an aldehyde group); OH (i.e. leading to a substitution with an -OC(=O)OH group), straight or branched Cj-C5 alkyl (i.e. leading to a substitution with a -OC(=O)R group), straight or branched Cj-C5 alkoxy (i.e. leading to a substitution by a -0C(=0)0R group) and a straight or branched Ci-C5 amine (i.e. leading to a substitution by a -OC(=O)NHR or -0C(=0)NRR' group).
In one embodiment of the present invention is a double bond. Thus, a compound of formula (II) is:
Figure imgf000007_0001
wherein R1, R6, R7, and R9 are have the same meaning as defined hereinabove.
In another embodiment of the present invention is a single bond. Thus, a compound of formula (II) is:
Figure imgf000007_0002
wherein Ri, R6, R7, and R9 are have the same meaning as defined hereinabove.
The term " diastereomeric ratio" as used herein is meant to encompass the ratio of the percentage of one diastereoisomer in a mixture to that of another diastereoisomer of a compound of formula (I).
Thus, in one embodiment when indicates a double bond, said diastereomeric ratio indicates the percentage ratio between (3R, AR, 6Λ)-diastereomer of a compound of general formula (I) (compound of formula (III)), and each of (3S, AR, 6R)- or (3R, 45, 65)-diastereomers, all of which (together or individually) may be present in said composition of the invention.
When a composition of the invention has a diastereomeric ratio of 50%:50%, it should be understood that the ratio between the (3R, AR, 6/?)-diastereomer of a compound of general formula (I) (compound of formula (III)) and any one of the diastereomers (35, AR, 6R)- or (3R, AS, 6S)- diastereomer, present in said composition is about 1 :1. When a composition of the invention has a diastereomeric ratio of about 100%:0%, it should be understood that the composition comprises essentially only the (3i?, AR, 6i?)-diastereomer of a compound of general formula (I), (compound of formula (III)). Thus, the composition of the present invention may comprise any mixture of (3R, AR, 6i?)-diastereomer of a compound of general formula (I) (compound of formula (III)) with one or more of its diastereomers ((35,4i?,6i?)- or (3R,AS,6S)- diastereomers), such as for example a composition having a diatereomeric ratio of 50%:50%, 70%:30%, 80%:20%, 90%: 10%, 95%:5%, 97%:3%, 99%: 1% or 100%:0%. In some embodiments of the invention, said diastereomeric ratio is at least 97%:3%.
Thus, in another embodiment when indicates a single bond, said diastereomeric ratio indicates the percentage ratio between (Ii?, 3R, AR, 6R)- diastereomer of a compound of general formula (I1) (compound of formula (IV))and each of (IS, 3R, AR, 6R)-, (\R, 35, AS, 65) , (\R, 35, AR, 6R)-, (15, 35, AR, 6R)-, (\R, 3R, AS, 6S)- or (15, 3R, AS, 65)-diastereomers, all of which (together or individually) may be present in said composition of the invention.
When a composition of the invention has a diastereomeric ratio of 50%:50%, it should be understood that the ratio between the (Ii?, 3i?, 4i?, 6i?)-diastereomer of a compound of general formula (I1) (compound of formula (IV)) and any one of the diastereomers (15, 3R, AR, 6R)-, (Ii?, 35, 45, 65) , (Ii?, 35, 4i?, 6R)-, (15, 35, AR, 6R)-, (Ii?, 3i?, 45, 65)- or (15, 3i?, 45, 65)-diastereomer, present in said composition is about 1:1. When a composition of the invention has a diastereomeric ratio of about 100%:0%, it should be understood that the composition comprises essentially only the (Ii?, 3i?, 4i?, 6i?)-diastereomer of a compound of general formula (I1) (compound of formula (IV)). Thus, the composition of the present invention may comprise any mixture of (Ii?, 3i?, 4i?, 6i?)-diastereomer of a compound of general formula (T) (compound of formula (IV)) with one or more of its diastereomers ((15, 3i?, 4i?, 6i?)-, (Ii?, 35, 45, 65) , (Ii?, 35, 4i?, 6i?)-, (15, 35, 4i?, 6i?)-, (Ii?, 3i?, 45, 65)- or (15, 3i?, 45, 65)- diastereomers), such as for example a composition having a diatereomeric ratio of 50%:50%, 70%:30%, 80%:20%, 90%: 10%, 95%:5%, 97%:3%, 99%: 1% or 100%:0%. In some embodiments of the invention, said diastereomeric ratio is at least 97%:3%.
In yet a further embodiment when indicates a single bond, said diastereomeric ratio indicates the percentage ratio between (15, 3i?, 4i?, 6i?)- diastereomer of a compound of general formula (I1) (compound of formula (IV)) and each of (li?, 3R, AR, 6R)-, (15, 35, 45, 65), (Ii?, 35, AR, 6R)-, (15, 35, AR, 6R)-, (Ii?, 3i?, 45, 65)- or (15, 3i?, 45, 65)-diastereomers, all of which (together or individually) may be present in said composition of the invention.
When a composition of the invention has a diastereomeric ratio of 50%:50%, it should be understood that the ratio between the (IS, 3R, AR, 6i?)-diastereomer of a compound of general formula (I1) (compound of formula (IV)) and any one of the diastereomers (Ii?, 3R, AR, 6R)-, (15, 35, 45, 65), (Ii?, 35, AR, 6R)-, (15, 35, AR, 6R)-, (Ii?, 3i?, 45, 65)- or (15, 3i?, 45, 65)-diastereomer, present in said composition is about 1:1. When a composition of the invention has a diastereomeric ratio of about 100%:0%, it should be understood that the composition comprises essentially only the (15, 3i?, 4i?, 6i?)-diastereomer of a compound of general formula (I1) (compound of formula (IV)). Thus, the composition of the present invention may comprise any mixture of (15, 3i?, 4i?, 6i?)-diastereomer of a compound of general formula (I1) with one or more of its diastereomers ((15, 3i?, 4i?, 6i?)-, (Ii?, 35, 45, 65) , (Ii?, 35, 4i?, 6i?)-, (15, 35, 4i?, 6i?)-, (Ii?, 3i?, 45, 65)- or (15, 3i?, 45, 65)-diastereomers), such as for example a composition having a diatereomeric ratio of 50%:50%, 70%:30%, 80%:20%, 90%:10%, 95%:5%, 97%:3%, 99%: 1% or 100%:0%. In some embodiments of the invention, said diastereomeric ratio is at least 97%:3%.
The term "diatereomeric excess" as used herein is meant to encompass the subtraction of the mole fraction of one diastereoisomer (D1) from the mole fraction of another diastereoisomer (D2) in a composition, i.e. D1 - D2. This term may alternatively relate to the percent diastereoisomer excess as 100%*(A-A>)-
Thus, in one embodiment when indicates a double bond, said diastereomeric excess indicates the excess in a composition of the invention of (3i?, 4i?, 6i?)-diastereomer of a compound of general formula (I) with respect to each of (35,4i?,6i?)-,or (3i?,45,65)-, diastereomer of compound of general formula (I), all of which (together or individually) may be present in said composition of the invention.
When the diastereomeric excess of a composition of the invention is 0% the mole fraction of (3i?, 4i?, 6i?)-diastereomer of a compound of general formula (I), is essentially equal to the mole fraction of any one of of (35, 4i?, 6R)-, or (3i?, 45, 65)- diastereomer of compound of general formula (I). When the diastereomeric excess of a composition of the invention is 100% the composition comprises substantially only the (3i?, 4i?, 6i?)-diastereomer of a compound of general formula (I). Thus, the composition of the present invention may comprise any mixture of (3i?, 4i?, 6i?)-diastereomer of a compound of general formula (I) with one or more of its diastereomers ((35,4i?,6i?)-, or (3i?,45,65)- diastereomers), such as for example a composition having a diastereomeric excess of 0%, 5%, 10%, 20%, 30%, 50%, 80%, 90%, 95%, 97%, 98%, 99%, or 100%. In some embodiments of the invention, said diastereomeric excess is at least 97%.
In another embodiment when indicates a single bond, said diastereomeric excess indicates the excess in a composition of the invention of (Ii?, 3i?, AR, 6R)- diastereomer of a compound of general formula (I1) (compound of formula (IV)) with respect to each of (15, 3R, AR, 6R)-, (Ii?, 35, 45, 65), (\R, 35, AR, 6R)-, (15, 35, AR, 6R)-, (\R, 3R, 45, 65)- or (15, 3R, 45, 65)-diastereomers, all of which (together or individually) may be present in said composition of the invention.
When the diastereomeric excess of a composition of the invention is 0% the mole fraction of (IR, 3R, AR, 6i?)-diastereomer of a compound of general formula (I1) (compound of formula (IV)), is essentially equal to the mole fraction of any one of (15, 3R, AR, 6R)-, (\R, 35, 45, 65) , (Ii?, 35, AR, 6R)-, (15, 35, 4i?, 6i?)-, (Ii?, 3i?, 45, 65)- or (15, 3i?, 45, 65)-diastereomers. When the diastereomeric excess of a composition of the invention is 100% the composition comprises substantially only the (Ii?, 3i?, 4i?, 6i?)- diastereomer of a compound of general formula (I1) (compound of formula (IV)). Thus, the composition of the present invention may comprise any mixture of (Ii?, 3i?, 4i?, 6i?)- diastereomer of a compound of general formula (I1) (compound of formula (IV)) with one or more of its diastereomers ((15, 3i?, 4i?, 6i?)-, (Ii?, 35, 45, 65) , (Ii?, 35, 4i?, 6i?)-, (15, 35, 4i?, 6i?)-, (Ii?, 3i?, 45, 65)- or (15, 3i?, 45, 65)-diastereomers), such as for example a composition having a diastereomeric excess of 0%, 5%, 10%, 20%, 30%, 50%, 80%, 90%, 95%, 97%, 98%, 99%, or 100%. In some embodiments of the invention, said diastereomeric excess is at least 97%.
In yet another embodiment when indicates a single bond, said diastereomeric excess indicates the excess in a composition of the invention of (15, 3i?, 4i?, 6i?)-diastereomer of a compound of general formula (I1) (compound of formula (IV)) with respect to each of (Ii?, 3i?, 4i?, 6i?)-, (15, 35, 45, 65), (Ii?, 35, 4i?, 6i?)-, (15, 35, 4i?, 6i?)-, (Ii?, 3i?, 45, 65)- or (15, 3i?, 45, 65)-diastereomers, all of which (together or individually) may be present in said composition of the invention.
When the diastereomeric excess of a composition of the invention is 0% the mole fraction of (15, 3i?, 4i?, 6i?)-diastereomer of a compound of general formula (I1) (compound of formula (IV)), is essentially equal to the mole fraction of any one of (Ii?, 3i?, 4i?, 6i?)-, (15, 35, 45, 65), (Ii?, 35, 4i?, 6i?)-, (15, 35, 4i?, 6i?)-, (Ii?, 3i?, 45, 65)- or (IiS, 3R, AS, 6S)-diastereomers. When the diastereomeric excess of a composition of the invention is 100% the composition comprises substantially only the (IS, 3R, AR, 6R)- diastereomer of a compound of general formula (I1) (compound of formula (IV)). Thus, the composition of the present invention may comprise any mixture of (IS, 3R, AR, 6R)- diastereomer of a compound of general formula (I1) (compound of formula (IV)) with one or more of its diastereomers ((IR, 3R, AR, 6R)-, (IS, 3S, AS, 6S), (IR, 3S, AR, 6R)-, (IS, 3S, AR, 6R)-, (\R, 3 R, AS, 6S)- or (IS, 3 R, AS, 6S)-diastereomers), such as for example a composition having a diastereomeric excess of 0%, 5%, 10%, 20%, 30%, 50%, 80%, 90%, 95%, 97%, 98%, 99%, or 100%. In some embodiments of the invention, said diastereomeric excess is at least 97%.
In another embodiment, a composition of the invention has an enantiomeric excess of between about 100% to more than about 0%.
The term "enantiomeric excess" (also denoted "ee") is meant to encompass a percent excess of an enantiomer (Ei or E2) over the racemic mixture (1 :1 mixture of Ei and E2), in accordance with eq.1 below:
F - F ee = * 100 = VoE1 - VoE2 (eq. 1)
F + F
Thus, where referring to ee value of 100% of, for example, enantiomer Ei it should be understood to encompass substantially only one enantiomer (Ei). When referring to ee value of more than about 0% of, for example, enantiomer Ei it should be understood to encompass non racemic mixtures of Ei and E2.
In one embodiment, when indicates a double bond, said ee indicates the percentage excess between the (3R, AR, 6R) stereoisomer of a compound of general formula (I) or (HI), and its enantiomer (3S, AS, 6S).
In another embodiment, when indicates a single bond, said ee indicates the percentage excess between the (Ii?, 3R, AR, 6R) stereoisomer of a compound of general formula (I1) or (IV), and its enantiomer (15, 3S, AS, 6S).
In yet a further embodiment, when indicates a single bond, said ee indicates the percentage excess between the (IS, 3R, AR, 6R) stereoisomer of a compound of general formula (I1) or (IV), and its enantiomer (Ii?, 35", AS, 6S).
In some embodiments, Ri is -R2OR3, wherein R2 and R3 are as defined hereinabove. In a further embodiment R2 is -CH2-. In some other embodiments R6 is H and R7 is -OR8, wherein R8 is a straight or branched C1-C5 alkyl. In other embodiments R7 is H and R6 is -OR8, wherein R8 is a straight or branched C1-C5 alkyl. In some other embodiments, R6 and R7 are each independently -OR8, wherein R8 is a straight or branched C1-C5 alkyl. In some other embodiments R9 is an optionally substituted branched C6-Ci2 alkyl.
As used herein, the term "alkyl" refers to a straight or branched chain hydrocarbon having from one to five carbon atoms, or from one to seven carbon atoms, or from five to nine carbon atoms, or from six to twelve carbon atoms. Examples of "alkyl" as used herein include, but are not limited to, methyl, ethyl, propyl, n-butyl, n- pentyl, isobutyl, and isopropyl, tert-butyl, and the like.
As used herein the term "alkylene" refers to a saturated, divalent, branched or straight hydrocarbon group having from one to five carbon atoms. Non-limiting examples of Ci-5-alkylene groups include, methylene, ethylene, 1 ,2-propylene, 1,3- propylene, butylene, isobutylidene, pentylene, hexylene and the like.
As used herein the term "ester" is meant to encompass an -COOR group wherein R is an alkyl as defined herein above.
A used herein the term "ether" refers to an -R'OR group, wherein R' is a Ci-C7 straight or branched alkylene group and R is a C1-C7 straight or branched alkyl group.
As used herein, the term "alkoxy" refers to an RO- group, where R is alkyl as defined above.
As used herein the term "Cj-Cγ amide" refers to a monoalkyl amide (-C0NHR) or dialkyl amide (-CONRR'), wherein R and R' are independently a Ci -C7 straight or branched alkyl.
As used herein the term "C1-C5 amine" refers to an -NHR or -NRR' group wherein R and R' are independently a Ci-C5 straight or branched alkyl.
As used herein the term "Cj-Cs alkoxy" refers to a -OR group wherein R is a Q- C5 alkyl.
As used herein the term "Cj-Cs ocyl" refers to a -C(=O)R group wherein R is a straight or branched CpC5 alkyl.
The term "optionally substituted" as used herein means that the groups in question are either unsubstituted or substituted with one or more of the substituents such as for example those specified above, phenyl, substituted phenyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen (-F, -Cl, -Br, -I). When the groups are substituted with more than one substituent the substituents may be the same or different and said substitution may occur at any position on the substituted group (i.e. at a terminal or any mid-chain position or both).
In an embodiment of the present invention, said compound of formula (II) is the following compound (HU-433):
(X).
Figure imgf000013_0001
In some embodiments of the invention said composition is a pharmaceutical composition. When referring to pharmaceutical compositions comprising a compound of the subject invention it should be understood to encompass admixtures of compounds of the invention, with pharmaceutically acceptable auxiliaries, and optionally other therapeutic agents. The auxiliaries must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.
Pharmaceutical compositions include those suitable for oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration or administration via an implant. The compositions may be prepared by any method well known in the art of pharmacy. Such methods include the step of bringing in association compounds used in the invention or combinations thereof with any auxiliary agent.
Auxiliary agent(s), also named accessory ingredient(s), include those conventional in the art, such as carriers, fillers, binders, diluents, disintegrants, lubricants, colorants, flavouring agents, anti-oxidants, and wetting agents.
Pharmaceutical compositions suitable for oral administration may be presented as discrete dosage units such as pills, tablets, dragees or capsules, or as a powder or granules, or as a solution or suspension. The active ingredient may also be presented as a bolus or paste. The compositions can further be processed into a suppository or enema for rectal administration.
The invention further includes a pharmaceutical composition, as hereinbefore described, in combination with packaging material, including instructions for the use of the composition for a use as hereinbefore described.
For parenteral administration, suitable compositions include aqueous and nonaqueous sterile injection. The compositions may be presented in unit-dose or multi-dose containers, for example sealed vials and ampoules, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of sterile liquid carrier, for example water, prior to use.
For transdermal administration, e.g. gels, patches or sprays can be contemplated. Compositions or formulations suitable for pulmonary administration e.g. by nasal inhalation include fine dusts or mists which may be generated by means of metered dose pressurized aerosols, nebulisers or insufflators.
The exact dose and regimen of administration of the composition will necessarily be dependent upon the therapeutic or nutritional effect to be achieved and may vary with the particular formula, the route of administration, and the age and condition of the individual subject to whom the composition is to be administered.
The inventors of the present application found that a composition comprising substantially HU-433, retained the CB2 specificity, with nearly 2-fold higher binding potency, and respective 1000- and 100-fold higher in vitro and in vivo skeletal activities, compared to HU-308. Thus, in some embodiments of the present invention there is provided a composition capable of binding to a CB receptor.
The term "CB receptor" is meant to encompass a cannabinoid G-protein coupled receptor, defined by their capability to bind to cannabinoids and/or endocannabinoids. In some embodiments said receptor is a CBl (cannabinoid receptor Type 1) and/or CB2 receptor (cannabinoid receptor Type 2). In other embodiments said receptor is a CB2 receptor (cannabinoid receptor Type 2).
CBl subtype receptor is mainly expressed in the brain, lungs, liver and kidneys. CB2 subtype receptor is mainly expressed in the immune system and in hematopoietic cells.
When referring to "binding" of a composition of the invention to a CB receptor it is meant to include any type of association between a composition of the invention and a CB receptor, which may activate said bound receptor.
In some embodiments said composition is capable of being bound to CBl and CB2 receptors. When both receptors are capable of being bound by a composition of the invention, the extent of binding may be identical or different. In some embodiments a composition of the invention binds to CB2 receptor to a greater extent as compared with the binding to CBl receptor. Thus resulting in an activation of CB2 receptor to a greater amount compared with activation of CBl receptor. In some embodiments activation of the CB2 receptor by a composition of the invention is at least 10 times higher than the activation of the CBl receptor. In other embodiments composition of the invention is capable of binding to CB2 receptor.
In other embodiments said binding of a CB receptor by a composition of the invention is associated with a beneficial therapeutic effect, such as the treatment of a disease or disorder. Examples of disease wherein a beneficial therapeutic effect is evident by activation of CB receptor (in some embodiments, with low or no activation of CBl receptor) are: inflammation (Benito et al., Brit. J. Pharmacol. 153, 277-285, 2008), pain, allergies, neurological diseases - multiple sclerosis (Docagne et al., Expert Opin. Therapeutic Targets, 12, 185-185, 2008), Alzheimer's (Benito et al., ibid), amyotropic lateral sclerosis (Kim et al., Eur J Pharmacol, 542, 100-105, 2006), HIV- induced encephalitis (Benoto et al., J. Neurosci. 25, 2530-2536, 2005), neuropathic pain (Zhang et al., Eur, J,. Neurosci, 17, 2750-2754, 2003); Huntington disease (Sagredo et al.. GUa, 57, 1154-1167 2009) ; Parkinson (Papa, SM. Exp. Neurol. 211, 334-338, 2008); Schizophrenia (Agid et al. Expert Opin Emerg Drugs., 13, 479-95, 2008). in liver diseasesin particular fibrogenesis associated with chronic liver diseases, ischaemia/reperfusion (I/R)-induced liver injury (Lotersztein et al., Brit. J. Pharmacol. 153, 286-289, 2008) and hepatic encephalopathy-associated with acute liver failure (Magen et al. Current Pharmaceutical Design. 14, 2362-2369, 2008), cerebral ischemic-reperfusion injury (Zhang et al., Neurosci. 152, 753-760, 2008); in cancer especially of hematopoietic origin (lymphoma and acute lymphocytic leukaemia), retinal vascularization, endometritis; appetite related disorders, metabolic syndrome, diabetes, and obesity. In some embodiments said disease or disorder is selected from inflammation, pain, allergies, neurological and neurodegenerative diseases, liver diseases, cerebral ischemic-reperfusion injury, cancer, retinal vascularization, endometritis, appetite related disorders, metabolic syndrome, diabetes, atherosclerosis and disorders related to anti-fibrinogenic effects and emesis or any combinations thereof.
In other embodiments a composition of the invention is for use in the stimulation of bone growth, bone mass, bone repair or prevention of bone loss.
In some other embodiments a composition of the invention is for the treatment of a disease or a disorder selected from osteopenia, osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, osteoarthritis, periodontal disease or defect, an osteolytic bone loss disease, post-plastic surgery, post-orthopedic surgery, post oral surgery, post-orthopedic implantation, and post-dental implantation, primary and metastatic bone cancer and osteomyelitis, or any combinations thereof. In some embodiments said disease or disorder is selected from osteopenia and osteoporosis.
In a further aspect, the present invention provides a use of a composition of the invention, for the manufacture of a medicament for activating a CB receptor.
In yet a further aspect, the invention provides a use a composition of the invention, for the manufacture of a medicament for stimulation of bone growth, bone mass, bone repair or prevention of bone loss.
In another aspect, the invention provides a use a composition of the invention, for the manufacture of a medicament for the treatment of a disease or a disorder selected from osteopenia, osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, osteoarthritis, periodontal disease or defect, an osteolytic bone loss disease, post-plastic surgery, post-orthopedic surgery, post oral surgery, post- orthopedic implantation, and post-dental implantation, primary and metastatic bone cancer, osteomyelitis, or any combinations thereof.
In a further aspect, the invention provides a method for activating a CB receptor in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a composition of the invention.
In yet a further aspect the invention provides a method of stimulation of bone growth, bone mass, bone repair or prevention of bone loss, said method comprising administering to a subject in need thereof a therapeutically effective amount of a composition of the invention.
The term "treatment" as used herein refers to the administering of a therapeutic amount of the composition of the present invention which is effective to ameliorate undesired symptoms associated with a disease, to prevent the manifestation of such symptoms before they occur, to slow down the progression of the disease, slow down the deterioration of symptoms, to enhance the onset of remission period, slow down the irreversible damage caused in the progressive chronic stage of the disease, to delay the onset of said progressive stage, to lessen the severity or cure the disease, to improve survival rate or more rapid recovery, or to prevent the disease form occurring or a combination of two or more of the above.
As used herein, the term "effective amount" means that amount of a composition of the invention that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician. The effective amount for purposes disclosed herein is determined by such considerations as may be known in the art. The amount must be effective to achieve the desired therapeutic effect as described above, depending, inter alia, on the type and severity of the disease to be treated and the treatment regime. The effective amount is typically determined in appropriately designed clinical trials (dose range studies) and the person versed in the art will know how to properly conduct such trials in order to determine the effective amount. As generally known, an effective amount depends on a variety of factors including the affinity of the ligand to the receptor, its distribution profile within the body, a variety of pharmacological parameters such as half life in the body, on undesired side effects, if any, on factors such as age and gender, etc. Furthermore, the term "therapeutically effective amount" means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function.
The invention further provides a composition comprising compound (1), said composition having a melting point of 44-450C and optical rotation of [α]o= -115°.
In a further aspect of the invention there is provided a method for preparing a compound of formula (II), said method comprising: esterification of a compound of formula (V) with an acyl chloride to obtain compound (VI):
Figure imgf000018_0001
(V) (VI) wherein acyl chloride may be any akyl chloride for example pivaloyl chloride; oxidation of compound (VI) to obtain 4-oxo-substituted compound (VII):
Figure imgf000018_0002
(VI) (VII) . reduction of 4-oxo-substituted compound (VII) to the 4-hydroxy- substituted compound (VIII):
Figure imgf000018_0003
(VII) (VIII) it is noted that such a reduction may give raise to both equatorial and axial hydroxyl substitution on position 4 of the bicyclic ring, with possible preference to the less sterically hindered substitution, such as for example the equatorial substitution. condensation of 4-hydroxy-substituted compound (VIII) with compound (IX) to obtain condensed compound (X):
Figure imgf000019_0001
(VIII) (IX) (X)
; without wishing to be bound by theory this condensation will occure preferably at the equatorial position which is less steriaclly hindered due to the position of the dimethyl bridge. reduction of ester group of condensed compound (X) to obtain compound of of formula (II):
Figure imgf000019_0002
(X) (H)
Such a reduction may also be obtained by hydrogenation of the ester group with agents such as for example LiAlH4 to obtain the corresponding hydroxyl group. It is noted that the substituents R2, R3, R6, R7, and R9 are all as defined herein above.
The present invention further concerns a method for the synthesis of HU-433, the method comprising: 1) esterification of (-) myrtenol [O:]D =-51O with pivaloyl chloride in dry pyridine , thereby obtaining myrtenyl pivalate;
2) oxidation of myrtenyl pivalate with Crθ3 and tBuOOH in CFbCN to obtain the 4-oxomyrtenyl pivalate having m.p. 35°C, [α]o=-162o;
3) reduction of 4-oxomyrtenyl pivalate with NaBH4 in ethanol to obtain 4- hydroxymyrtenyl pivalate;
4) condensation of 4-hydroxymyrtenyl pivalate with 5-dimethylheptyl-resorcinol (5-DMH-resorcinol), in the presence of pTSA, to obtain 2-(3-myrtenyl pivalate)-5- dimethylheptyl resorcinol;
5) methylation of 2-(3-myrtenyl pivalate)-5-dimethylheptyl resorcinol with methyl iodide and potassium carbonate to give 2-(3-myrtenyl pivalate)-5- dimethylheptyl dimethylresorcinol (HU-433 pivalate);
6) reaction of 2-(3 -myrtenyl pivalate)-dimethylheptyl dimethyl resorcinol (HU- 433 pivalate) with LiAlH4 to yield the desired (-)-2-(3-myrtenyl)-5-dimethylheptyl resorcinol (HU-433), (-) isomer with m.p. 44-45°C, [α]D= -115°.
The present invention further concerns compounds obtainable by the above method.
It must be noted that, as used in this specification and the appended claims, the singular forms "a", "an" and "the" include plural referents unless the content clearly dictates otherwise.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", should be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any integer or step or group of integers and steps.
BRIEF DESCRIPTION OF THE DRAWINGS
In order to understand the invention and to see how it may be carried out in practice, embodiments will now be described, by way of non-limiting example only, with reference to the accompanying drawings, in which:
Figs. 1A-1B shows column diagram describing the stimulation of MC3T3 El osteoblastic cell number by a compound of the present invention (i.e. HU-433) (Fig. IA) and HU-308 (Fig. IB) (shown as [cell per WeIl]XlO"4 as a function of compound concentration (M). Data is mean±S.E. obtained in 3 culture wells per condition). ND, not done.
Figs. 2A-2B shows column diagram describing the rescue of ovariectomy (OVX)-induced loss of trabecular bone volume density (BV/TV) by a compound of the present invention (i.e. HU-433) and HU-308. Treatment commenced 6 weeks after OVX, to allow initial bone loss, and consisted of 6-week intraperitoneal administration of: 0.2 mg/Kg/day HU-433 (Fig. 2A); 20 mg/Kg/day HU-308 (Fig. 2B). μCT analysis. Data are mean±S.E. obtained in 6 mice per condition. (*) p< 0.05.
DETAILED DESCRIPTION OF EMBODIMENTS
The following Examples are representative of techniques employed by the inventors in carrying out aspects of the present invention. It should be appreciated that while these techniques are exemplary of preferred embodiments for the practice of the invention, those of skill in the art, in light of the present disclosure, will recognize that numerous modifications can be made without departing from the spirit and intended scope of the invention.
Example 1: Synthesis of HU-433
1. Preparation of Myrtenyl pivalate
Figure imgf000021_0001
Pivaloyl chloride (8g, 67mmol) was added slowly to a solution of myrtenol (commercial myrtenol; Aldrich CAS# 19894-97-4), [α]D= -51°) (5g, 33mmol) in dry pyridine (25ml), with cooling in ice bath. The mixture was stirred overnight at room temperature. Then the mixture was diluted with ether (25ml) and ice water was added, the organic layer collected and washed with 10% HCl several times, then with NaHCO3, dried over Na2SO4 and evaporated to give 7.17g (91 %) colorless oil.
2. Preparation of 4-Oxomyrtenyl pivalate:
Figure imgf000022_0001
For the preparation of 4-oxomyrtenyl pivalate, CrO3 (1.06g, lO.όmmol) was dissolved in CH3CN (35ml) and stirred at O0C. Then t-BuOOH (17.5ml 70%/H2O, 126mmol) was added followed by the immediate addition of a solution of myrtenyl pivalate (5g, 20mmol) in CH3CN (38ml). The reaction mixture was brought to room temperature and was stirred for Ih. The reaction mixture was diluted with ether, and 10% Na2SO3 in water (130ml) was added. The mixture was extracted several times with ether, dried and evaporated. The crude mixture was purified by silica gel column chromatography (0-10% ether in petroleum ether) to give an oil that crystallized from pentane to give 4-oxo-myrtenyl pivalate (0.9g, 19%) m.p. 35°C, [α]o= -162°.
3. Preparation of 4-Hydroxymyrtenyl pivalate:
Figure imgf000022_0002
4-Oxo-myrtenyl pivalate (Ig, 4mmol) was dissolved in ethanol (15ml). NaBH4 (0.2g, 5.3mmol) was added slowly and the resulting suspension was stirred at room temperature for 15 min. The ethanol was evaporated, then ether and water were added. The organic layer was separated, dried and evaporated to give a colorless oil (0.92g, 91%).
4. Condensation of 4-Hydroxymyrtenyl pivalate with DMH-resorcinol:
Figure imgf000022_0003
To a solution of dry pTSA (0.16g, 0.96mmol) and 1,1 -DMH-resorcinol (0.86g, 3.44mmol) in dry dichloromethane (125ml) and under argon atmosphere, was added slowly a solution of 4-hydroxy-myrtenyl pivalate (0.88g, 3.49mmol) in dry dichloromethane (30ml). The mixture was stirred at room temperature for 1.5h. A saturated NaHCO3 solution was added and the organic layer was then washed twice with water, dried and evaporated. The residue was purified by column chromatography on silica gel in ether/pet.ether (5:95) to give 0.71g (43%) 2-(3-myrtenyl pivalate)-5- dimethylheptyl-resorcinol, a colorless oil. 5. Methylation:
Figure imgf000023_0001
Methyl iodide (0.75ml, 12mmol) was added to a solution of 2-(3-myrtenyl pivalate)-5-dimethylheptyl resorcinol (0.7 Ig, 1.51mmol) and K2CO3 (1.6g, 12mmol) in dry DMF (5 ml). After stirring at room temperature for 24h, the mixture was diluted with water (40ml) and extracted with ether. The organic layer was washed with water, dried and evaporated. Purification by column chromatography on silica gel with etherpetroleum ether (5:95) gave 0.5 Ig (67%) 2-(3-myrtenyl pivalate)-5-dimethylheptyl resorcinol (HU-433, pivalate) a colorless oil
6. Preparation of HU-433
Figure imgf000023_0002
HU-433 pivalate (0.35g, 0.7mmol) in dry ether (20ml) was added slowly, under argon to a suspension of LiAlH4 (64 mg, 1.68mmol) an dry ether (5ml). The mixture was refluxed for 2h. The excess LiAlH4 was destroyed with ethyl acetate followed by a saturated solution of MgSO4 until a clear ether solution was obtained. The ether layer was decanted, dried and evaporated. The product precipitated out from pentane to give HU-433, m.p. 44-45°C, [α]D= -115° HU-433 spectral data: 1H-NMR (CDCl3): 3.741 (s, 6H CH3O-), 3.998 (t, J=2.1Hz, IH allylic), 4.069(d, J=5.7 Hz, 2H, -CH2OH), 5.704(t, J=1.2, IH, olefinic) 6.483 (s, 2H, aromatic). MS calc/found: m/z 414.37/437.27 (m+Na)
Example 2: Binding affinity of HU-433 vs. HU-308 to CBl and CB2 cannabinoid receptors
Binding of HU-308 to the CBl and CB2 cannabinoid receptors was assayed (see Hanus et al, 1999), showing Kj value of 22.7 nM. Binding of HU-433 was found to be significantly more potent, having K, value of 12.2 nM.
For CBl receptor binding, synaptosomal membranes were prepared from the brains of Sabra rats by homogenization and gradient centrifugation (Devane et al, 1992). For CB2 receptor binding assay, COS- 7 cells were transfected with plasmids containing CB2 cDNA, and crude membranes were prepared (Munro et al, 1993).
The high affinity receptor probe, [3H]HU-243 (Tocris Cookson Ltd., United Kingdom), with a dissociation constant of 45±7 pM for the CBl receptor, was incubated with synaptosomal membranes (3—4 μg) for CBl assay or transfected cells for the CB2 assay, for 90 min at 300C with different concentrations of the assayed ligands or with the vehicle alone (fatty acid-free bovine serum albumin at a final concentration of 0.5 mg/ml).
Bound and free radioligands were separated by centrifugation. The data were normalized to 100% of specific binding, which was determined with 50 nM unlabeled HU-243.
Hanus et al., showed that HU-308 did not bind to CBl receptor however showed potent binding to CB2 receptor (Table 1). In the present example it was shown that HU- 433 did not bind to CBl receptor. The binding of HU-433 to CB2 receptor was nearly twice more potent compared to HU-308 (Table 3).
Table 3: Binding of HU-433 and HU-308 to CBl and CB2 receptors
Ki
LigandVReceptor CBl CB2
HU-433 >20 μM 12.2 nM HU-308 >10 μM 22.7 nM
Example 3: Comparative skeletal activity of HU-433 and HU-308 Osteoblastic MC3T3 El cells were cultured as reported in Miguel et al, 2005. For the last 46 hours in culture the cell were incubated with HU-433 or HU-308 added as a DMSO solution. Control cultures were treated only with the DMSO solvent (Ofek et al, 2006). In these cells, HU-433 and HU-308 doubled cell number at respective ligand concentrations of 10"11M and 10"8M, indicating that in the assay of HU-433 was a 1000-fold more active compared to HU-308 (Figs. IA and IB). Typical of this assay system, the dose-response curves are bell shaped (Miguel et al, 2005), with the peak stimulation of cell number followed by reversal of the effect to baseline levels.
Based on the in vitro screening, the in vivo skeletal activity of HU-433 and HU- 308 was analyzed in an ovariectomy (removal of ovaries; OVX) mouse model, the most widely used animal model for osteoporosis. Using this experimental system for testing bone anabolic activity, OVXed mice are left untreated to allow for bone loss to occur, followed by a treatment period intended for reversal of the bone loss (Alexander et al, 2001).
A micro-computed tomographic (μCT) analysis of L3 vertebrae indicated that HU-433, at 0.2 mg/Kg/day for 6 weeks significantly rescued almost the entire OVX- induced trabecular bone loss, whereas HU-308 reversed only 50% of the bone loss, and only at 20 mg/Kg/day for 6 weeks (Figs. 2A and 2B). Thus, in vivo, HU-433 is at least 100-fold more active than HU-308 (at a 100 fold increase it only caused 50% of the HU-433 effect). The effect of HU-433 in above in vivo test system is substantially greater than the reversal of bone volumetric density by parathyroid hormone (1-34), the only clinically approved bone anabolic agent (Alexander et al, 2001).

Claims

CLAIMS:
1. A composition comprising the (37?, AR, 6Z?)-diastereomer of a compound of general formula (II):
Figure imgf000026_0001
said composition having diastereomeric ratio of between about 50%:50% to about 100%:0%; wherein is a single or double bond;
Ri is independently selected from -R2OR3, -Q=O)R4, -OQ=O)R5;
R2 is a Ci-C5 straight or branched alkylene;
R3 is selected from the group consisting of H, -C(=O)OH, straight or branched C1-C5 alkyl, straight or branched Ci-C5 acyl, straight or branched C1-C5 amide;
R4, and R5 are independently selected from the group consisting of H, OH, straight or branched Ci-C5 alkyl, straight or branched Cj-C5alkoxy, straight or branched C1-C5 amine;
R6 and R7 are each independently selected from H, and -OR8 wherein R8 is H, or a straight or branched Ci-C5 alkyl, provided that at least one of R^ and R7 is different than H; and
R9 is independently selected from an optionally substituted straight or branched C6-Ci2 alkyl, an optionally substituted straight or branched C5-C9 alkoxy, an optionally substituted straight or branched C1-C7 ether.
2. A composition comprising the (3/?,4i?,6i?)-diastereomer of a compound of general formula (II):
Figure imgf000027_0001
said composition having diatereomeric excess of between about 0% to about 100%; wherein is a single or double bond;
R1 is independently selected from -R2OR3, -CC=O)R4, -OC(=O)R5;
R2 is a C1-C5 straight or branched alkylene;
R3 is selected from the group consisting of H, -C(=O)OH, straight or branched C1-C5 alkyl, straight or branched C1-C5 acyl, straight or branched C1-C5 amide;
R4, and R5 are independently selected from the group consisting of H, OH, straight or branched C1-C5 alkyl, straight or branched CrC5alkoxy, straight or branched C1-C5 amine;
R6 and R7 are each independently selected from H, and -OR8 wherein R8 is H or a straight or branched C1-C5 alkyl, provided that at least one of R$ and R7 is different than H; and
R9 is independently selected from an optionally substituted straight or branched C6-C12 alkyl, an optionally substituted straight or branched C5-C9 alkoxy, an optionally substituted straight or branched Ci-C7 ether.
3. A composition according to claim 1 , wherein said diastereomeric ratio is at least 97%:3%.
4. A composition according to claim 2, wherein said diastereomeric excess is at least 97%.
5. A composition according to claims 1 or 2, having an enantiomeric excess of between about 100% to more than about 0%.
6. A composition according to any one of the preceding claims, wherein is a double bond.
7. A composition according to any one of claims 1 to 5, wherein is a single bond.
8. A composition according to any one of the preceding claims, wherein R1 is -R2OR3, wherein R2 and R3 are as defined hereinabove.
9. A composition according to claim 8, wherein R2 is -CH2-.
10. A compound according to any one of the preceding claims wherein R6 is H and R7 is -OR8, wherein R8 is a straight or branched -C1-C5 alkyl.
11. A compound according to any one of the preceding claims wherein R7 is H and R6 is -OR8, wherein R8 is a straight or branched -C1-C5 alkyl.
12. A composition according to any one of the preceding claims, wherein R6 and R7 are each independently -OR8, wherein R8 is a straight or branched -Ci-C5 alkyl.
13. A composition according to any one of the preceding claims, R9 is an optionally substituted branched -C6-Ci2 alkyl.
14. A composition according to any one of the preceding claims, wherein said compound of formula (II) is:
Figure imgf000028_0001
(i).
15. A composition according to any one of the preceding claims, being a pharmaceutical composition.
16. A composition according to any one of the preceding claims capable of binding to a CB receptor.
17. A composition according to claim 16, wherein said receptor is a CB2 receptor.
18. A composition according to claims 16 or 17, wherein said binding is associated with the treatment of a disease or disorder.
19. A composition according to claim 18, wherein said disease or disorder is selected from inflammation, pain, allergies, neurological and neurodegenerative diseases, liver diseases, cerebral ischemic-reperfusion injury, cancer, retinal vascularization, endometritis, appetite related disorders, metabolic syndrome, diabetes, atherosclerosis; disorders related to anti-fibrinogenic effects and emesis.
20. A composition according to any one of the preceding claims for use in the stimulation of bone growth, bone mass, bone repair or prevention of bone loss.
21. A composition according to any one of the preceding claims, for the treatment of a disease or a disorder selected from osteopenia, osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, osteoarthritis, periodontal disease or defect, an osteolytic bone loss disease, post-plastic surgery, post-orthopedic surgery, post oral surgery, post-orthopedic implantation, and post-dental implantation, primary and metastatic bone cancer, osteomyelitis, or any combinations thereof.
22. A composition according to claim 21, wherein said at least one disease or disorder is selected from osteopenia and osteoporosis.
23. Use of a composition according to claims 1 to 22, for the manufacture of a medicament capable of binding to a CB receptor.
24. Use according to claim 23, wherein said receptor is a CB2 receptor.
25. Use according to claims 23 or 24, wherein said binding is associated with the treatment of at least one disease or disorder.
26. Use according to claim 25, wherein said at least one disease or disorder is selected from inflammation, pain, allergies, neurological and neurodegenerative diseases, liver diseases, cerebral ischemic-reperfusion injury, cancer, retinal vascularization, endometritis, appetite related disorders, metabolic syndrome, diabetes, atherosclerosis; disorders related to anti-fibrinogenic effects and emesis.
27. Use a composition according to claims 1 to 22, for the manufacture of a medicament for stimulation of bone growth, bone mass, bone repair or prevention of bone loss.
28. Use a composition according to claims 1 to 22, for the manufacture of a medicament for the treatment of a disease or a disorder selected from osteopenia, osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, osteoarthritis, periodontal disease or defect, an osteolytic bone loss disease, post-plastic surgery, post-orthopedic surgery, post oral surgery, post-orthopedic implantation, and post-dental implantation, primary and metastatic bone cancer, osteomyelitis, or any combinations thereof.
29. Use according to claim 28, wherein said at least one disease or disorder is selected from osteopenia and osteoporosis.
30. A method for binding a CB receptor in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a composition according to any one of claims 1 to 22.
31. A method according to claim 30, wherein said CB receptor is a CB2 receptor.
32. A method according to claim 31, wherein said binding is associated with the treatment of at least one disease or disorder.
33. A method according to claim 32, wherein said at least one disease or disorder is selected from inflammation, pain, allergies, neurological and neurodegenerative diseases, liver diseases, cerebral ischemic-reperfusion injury, cancer, retinal vascularization, endometritis, appetite related disorders, metabolic syndrome, diabetes, atherosclerosis; disorders related to anti-fibrinogenic effects and emesis.
34. A method of stimulation of bone growth, bone mass, bone repair or prevention of bone loss, said method comprising administering to a subject in need thereof a therapeutically effective amount of a composition according to any one of claims 1 to 22.
35. The method according to claim 34, for the treatment of at least one disease or a disorder selected from osteopenia, osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, osteoarthritis, periodontal disease or defect, an osteolytic bone loss disease, post-plastic surgery, post-orthopedic surgery, post oral surgery, post-orthopedic implantation, and post-dental implantation, primary and metastatic bone cancer, osteomyelitis, or any combinations thereof.
36. The method according to claim 35, wherein said at least one disease or disorder is selected from osteopenia and osteoporosis.
37. A method for preparing a compound of formula (II), said method comprising: esterification of a compound of formula (V) with an acyl chloride to obtain compound (VI):
Figure imgf000031_0001
(V) (VI) . oxidation of compound (VI) to obtain 4-oxo-substituted compound (VII):
Figure imgf000031_0002
(VI) (VII) . reduction of 4-oxo-substituted compound (VII) to the 4-hydroxy- substituted compound (VIII):
Figure imgf000031_0003
(VII)
(VIII) ; condensation of 4-hydroxy-substituted compound (VIII) with compound (IX) to obtain condensed compound (X):
Figure imgf000032_0001
(VIII) (IX) (X)
reduction of ester group of condensed compound (X) to obtain compound of formula (II):
Figure imgf000032_0002
(X) (H)
PCT/IL2009/000964 2008-10-06 2009-10-11 Compositions comprising cb receptor agonists, uses thereof and methods for their preparation WO2010041253A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP09760006.8A EP2346804B1 (en) 2008-10-06 2009-10-11 Composition comprising cb receptor agonists and uses thereof
US13/122,662 US9428431B2 (en) 2008-10-06 2009-10-11 Compositions comprising CB receptor agonists, uses thereof and methods for their preparation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10305408P 2008-10-06 2008-10-06
US61/103,054 2008-10-06
US16501109P 2009-03-31 2009-03-31
US61/165,011 2009-03-31

Publications (1)

Publication Number Publication Date
WO2010041253A1 true WO2010041253A1 (en) 2010-04-15

Family

ID=41666423

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2009/000964 WO2010041253A1 (en) 2008-10-06 2009-10-11 Compositions comprising cb receptor agonists, uses thereof and methods for their preparation

Country Status (3)

Country Link
US (1) US9428431B2 (en)
EP (1) EP2346804B1 (en)
WO (1) WO2010041253A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549906B2 (en) 2013-11-20 2017-01-24 Mary Lynch Compositions and methods for treatment of ocular inflammation and/or pain
WO2022036455A1 (en) * 2020-08-21 2022-02-24 Altus Formulation Inc. Dual analgesic/anti-inflammatory compositions comprising cb2 receptor agonists, combinations, and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282248A (en) * 1978-08-02 1981-08-04 Raphael Mechoulam Pinene derivatives and pharmaceutical compositions containing the same
WO2003005960A2 (en) * 2001-07-13 2003-01-23 University Of Connecticut Novel bicyclic and tricyclic cannabinoids
US20070248702A1 (en) * 2004-06-22 2007-10-25 Javier Fernandez-Ruiz Use of CB2 receptors agonists for the treatment of Huntington's disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434295A (en) * 1994-02-07 1995-07-18 Yissum Research Development Company Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds
IL132661A (en) 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for the peripheral cannabinoid receptor
ATE394124T1 (en) 2002-06-06 2008-05-15 Yissum Res Dev Co METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR MODULATING BONE GROWTH

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282248A (en) * 1978-08-02 1981-08-04 Raphael Mechoulam Pinene derivatives and pharmaceutical compositions containing the same
WO2003005960A2 (en) * 2001-07-13 2003-01-23 University Of Connecticut Novel bicyclic and tricyclic cannabinoids
US20070248702A1 (en) * 2004-06-22 2007-10-25 Javier Fernandez-Ruiz Use of CB2 receptors agonists for the treatment of Huntington's disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEVIN S ET AL: "STRUCTURAL FEATURES AFFECTING CHIRAL RESOLUTION OF CANNABIMIMETIC ENANTIOMERS BY AMYLOSE 3,5-DIMETHYLPHENYLCARBAMATE CHIRAL STATIONARY PHASE", CHIRALITY, WILEY-LISS, NEW YORK, US, vol. 7, no. 3, 1 January 1995 (1995-01-01), pages 140 - 146, XP009007782, ISSN: 0899-0042 *
MECHOULAM R ET AL: "Cannabimimetic activity of novel enantiomeric, benzofuran cannabinoids", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 33, no. 3, 1 January 1990 (1990-01-01), pages 1037 - 1043, XP002414722, ISSN: 0022-2623 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549906B2 (en) 2013-11-20 2017-01-24 Mary Lynch Compositions and methods for treatment of ocular inflammation and/or pain
WO2022036455A1 (en) * 2020-08-21 2022-02-24 Altus Formulation Inc. Dual analgesic/anti-inflammatory compositions comprising cb2 receptor agonists, combinations, and methods of use thereof

Also Published As

Publication number Publication date
EP2346804A1 (en) 2011-07-27
US9428431B2 (en) 2016-08-30
EP2346804B1 (en) 2017-03-08
US20110269842A1 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
KR100840925B1 (en) NOVEL INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-αMODULATORS, SYNTHESES OF SAID MODULATORS AND METHODS OF USING SAID MODULATORS
JP2012509351A (en) Fluorination of organic compounds
JP2005535712A (en) Resolvin: Biotemplate for therapeutic treatment
WO2012171969A1 (en) HYDROGENATION OF KETONES HAVING AT LEAST A CARBON-CARBON DOUBLE BOND IN THE γ, δ-POSITION
EP2346804B1 (en) Composition comprising cb receptor agonists and uses thereof
JP2021509909A (en) 3-Phenyl-4-hexinic acid derivative as a GPR40 agonist
JP6983161B2 (en) Fencanfamin prodrug
WO2009047791A2 (en) Toll like receptor (tlr) signaling antagonist
US20150119406A1 (en) Tricyclic pyrone compounds reduce amyloid beta aggregates
CN114555548A (en) Process for the production of cannabinoids and cannabinoid acids
CN1127250A (en) 2,3-bridged 1,4-dihydropyridines, process for their preparation and their use as medicaments
CA2805292A1 (en) (20r,25s)-2-methylene-19,26-dinor-1.alpha.,25-dihydroxyvitamin d3 in crystalline form
CN101619040A (en) Aporphine compound, medicinal composition thereof and application thereof
JP5898768B2 (en) Indene derivatives for use in the treatment of inflammatory bowel disease
KR20120081120A (en) Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity
FI78289B (en) FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT ANVAENDBARA BICYKLO / 3.2.0 / HEPTAN-6-ONOXIMETERDERIVAT.
JP6329901B2 (en) Crystallization of 1α-hydroxy-20-methyl-2-methylene-19,24,25,26,27-pentanorvitamin D3
CN101516841B (en) Improved method of production of 9-cis-retinoic acid
MX2007013844A (en) Diamondoid derivatives possessing therapeutic activity.
WO2014173957A2 (en) Compound
JP4345311B2 (en) Antioxidant
KR20140020300A (en) Method for manufacturing phosphonocrotonic acid derivative
Frąckowiak et al. Stereochemistry of terpene derivatives. Part 4: Fragrant terpenoid derivatives with an unsaturated gem-dimethylbicyclo [3.1. 0] hexane system
WO2007110109A1 (en) Novel method

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09760006

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2009760006

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009760006

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 3208/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 13122662

Country of ref document: US